CareDx (CDNA) shares were up over 30% in Thursday trading after the company said a final policy affirmed coverage across its transplant surveillance offerings in kidney, heart, and lung.
The firm reported earlier the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.
The final Local Coverage Determination is expected to take effect on Aug. 30, CareDx added.
Price: $39.01, Change: $+9.26, Percent Change: +31.11%